新浪登录
腾讯登录美国分子诊断公司2014亏损790万美元
| 导读 | 美国创新性分子诊断公司Signal Genetics2014年亏损达790万美元，美创新性分子诊断行业是否将陷入低潮？ |
Signal Genetics最近在其10-K会议上声明表示其2014年全年净利润增长值去上一年度持平，达430万美元。
同时，这家分子诊断公司在声明中表示其2014年归属于股东与公司成员的股票净亏损达790万美元，而这一数字在2013年仅为240万。折合2014年每股亏损3.5美元，这一数字在2013年是12.23美元。
Signal Genetics于2014年6月上市，上市同时投入了230万股稀释其股价，而2013年该公司仅投入市场20万股。
2014年，该公司的研发投入由2013年的22.5万美元提升至29.3万美元，而其销售成本从180万美元飙升至780万美元。
该公司于2014年以510万美元的现金完成了财政收尾，而在2014年底，Signal Genetics通过公开发行普通股筹集了900万美元。
立足于纽约的分子诊断公司Signal Genetics提供应用MyPRS芯片基因的表达谱分析服务，预测病人多发性骨髓瘤的早期复发风险，帮助临床医生对患者进行分类并通过对不同突变进行甄别进而影响医生为不同病人制定个性化治疗方案。（转化医学网360zhyx.com）以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。
转化医学网推荐的新闻阅读：
NEW YORK (GenomeWeb) – Signal Genetics said in its Form 10-K today that its full-year 2014 revenue growth was flat year over year at $4.3 million.The molecular diagnostics firm also said that its net loss attributable to shareholders and company members was $7.9 million in 2014, compared to a net loss of $2.4 million in 2013. On a per-share basis, net loss retreated to $3.50 in 2014 compared to $12.23 in 2013.
Signal Genetics, which went public in June 2014, used about 2.3 million shares to calculate its net loss on a per-share basis in 2014, and 200,000 shares to calculate its 2013 loss-per-share figure, it said.
Its R&D costs rose to $293,000 from $225,000, while its SG&A costs spiked to $7.8 million from $1.8 million.
The company finished 2014 with $5.1 million in cash. Pursuant to the end of 2014, Signal raised $9 million in gross proceeds in a public offering of its common shares.
New York City-based Signal offers the MyPRS microarray-based gene expression profile assay for predicting a patient's risk of early relapse for multiple myeloma. It enables physicians to stratify their patients and treatment options and identify genomic alterations that may affect which therapies doctors choose.
还没有人评论，赶快抢个沙发